Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka/Astex’s Oral AML Drug Nabs European OK
Otsuka Pharmaceutical said on September 19 that European regulatory authorities have approved Inaqovi, a fixed-dose combination of decitabine and cedazuridine originated by US unit Astex Pharmaceuticals, for the treatment of acute myeloid leukemia (AML). The European Commission gave the green…
To read the full story
Related Article
- Otsuka/Astex’s AML Medicine Accepted for Review in Europe
August 23, 2022
- Astex’s Inqovi Gets Approval in US, Canada: Otsuka
July 9, 2020
- Astex’s Novel Cancer Drug Accepted for FDA Review: Otsuka
February 13, 2020
BUSINESS
- FRONTEO, Daiichi Sankyo Build AI Model to Analyze Toxicity Reports
July 15, 2026
- Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
- iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
- FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
July 14, 2026
- Santen, Kyorin Strike Co-Promotion Deal for Alesion Eyelid Cream
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…